JIR
JNP

James Investment Research’s Juniper Pharmaceuticals, Inc. Common Stock JNP Stock Holding History

James Investment Research’s Portfolio JNP Stock Details JNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-118,930
Closed -$815K – 550
2014
Q2 		$815K Buy
118,930
+60,980
+105% +$408K 0.03% 232
2014
Q1 		$418K Buy
+57,950
New +$400K 0.01% 286

Other funds holding JNP

BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
PCM
Perritt Capital Management Chicago, Illinois $59.8M AUM 26.94% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

James Investment Research's JNP Position: Q3 2014 in Review

James Investment Research sold out of Juniper Pharmaceuticals, Inc. Common Stock (JNP) in Q3 2014, closing a stake of 118,930 shares — an estimated $815K sold.

James Investment Research first reported a position in JNP in Q1 2014 and held it in 2 quarters. The position peaked at $815K in Q2 2014. 36 funds tracked by Wall St. Rank hold JNP as of Q3 2014.

  • James Investment Research reported no remaining Juniper Pharmaceuticals, Inc. Common Stock position as of Q3 2014 after selling out during the quarter.
  • James Investment Research sold 118,930 Juniper Pharmaceuticals, Inc. Common Stock shares in Q3 2014, an estimated $815K.
  • James Investment Research first reported a position in Juniper Pharmaceuticals, Inc. Common Stock in Q1 2014 and held it in 2 quarters.
  • James Investment Research's Juniper Pharmaceuticals, Inc. Common Stock position peaked at $815K in Q2 2014.
  • 36 funds tracked by Wall St. Rank held Juniper Pharmaceuticals, Inc. Common Stock as of Q3 2014.

Based on James Investment Research's 13F filing for Q3 2014, filed 9 Oct 2014.